Quantum Genomics disclosed the final results of phase I clinical trials for QGC001 during the joint Meeting of the European and International Societies of Hypertension (ESH-ISH) in Athens (Greece)

Quantum Genomics, (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, in scientific collaboration with Dr. Catherine Llorens-Cortes (INSERM U1050/Collège de France), presented during the Congress HYPERTENSION 2014, held in Athens from June 13th to 16th, the final results of the clinical trials Phase I of its drug candidate QGC001. 2014/06/18

Télécharger le pdf